WINT

Windtree is a clinical-stage cardiovascular/oncology biotech with no product revenue and no path to it near-term: its lead asset, istaroxime, is still only a Phase 2 candidate for acute heart failure and cardiogenic shock, and the MD&A concedes that without marketing approval 'we will not be able to commercialize, or generate any revenues.' The headline FY2024 net loss of -$1.79M is deeply misleading — it is flattered by a $14.5M non-cash gain on debt extinguishment (the Deerfield settlement) and a $10.5M swing in warrant fair value. The real economics are the -$26.1M operating loss and -$15.4M of operating cash burn, against just $1.78M of cash (down 58.8% YoY) and $2.57M of current assets versus $5.72M of current liabilities. That is a company operating on fumes.

The capital structure tells the story of survival-by-dilution. The filing references First and Second PIPEs, July 2024 Warrants, senior convertible notes, an ELOC commitment note, and a 1-for-50 reverse split effective February 2025 that collapsed shares outstanding to 3.56M (down 61.3% YoY). The accumulated deficit is -$847M — nearly a billion dollars incinerated over the company's life — and the annual net-loss history (-$32.6M, -$67.6M, -$39.2M, -$20.3M) confirms a chronic cash-consuming model. Even paying $657K in dividends while burning operating cash and impairing the rostafuroxin intangible underscores questionable capital discipline.